Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

BACKGROUND: Neoadjuvant programmed death receptor-1 (PD-1) inhibitors have drawn increasing attention in locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, we investigated the safety and efficacy of gemcitabine and cisplatin (GP), combined with a PD-1 inhibitor, in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiaotao, Liu, Qiaodan, Zhong, Guihua, Peng, Yingpeng, Liu, Ye, Liang, Lizhong, Hong, Haiyu, Feng, Weineng, Yang, Shuang, Zhang, Yaqin, Xian, Shiping, Li, Zhanyu, Zhou, Yuling, Zhang, Zhaoyuan, Jiang, Wen, Liang, Jun, Liu, Zhi-gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558942/
https://www.ncbi.nlm.nih.gov/pubmed/36224603
http://dx.doi.org/10.1186/s13046-022-02510-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558942/
https://www.ncbi.nlm.nih.gov/pubmed/36224603
http://dx.doi.org/10.1186/s13046-022-02510-2

Ejemplares similares